SWOG Cancer Research Network: Carcinoma, Non-Small-Cell Lung trials

The registry lists 30 Carcinoma, Non-Small-Cell Lung studies with SWOG Cancer Research Network as lead sponsor. 5 are open to participants now and 10 have results posted.

Phase 1 1Phase 2 22Phase 3 7No phase 3(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Treatment for Advanced Non-small Cell Lung Cancer With Actionable Genomic Alterations After Targeted Treatment and Chemotherapy (An Expanded Lung-MAP Treatment Trial)RecruitingNCT07393555Phase 2
• Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)RecruitingNCT06616584Phase 2/3
• Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)RecruitingNCT06116682Phase 2
• Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)RecruitingNCT06031688Phase 2
• Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)RecruitingNCT05642572Phase 2
• Combination Treatment (Talazoparib Plus Avelumab) for Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer With STK11 Gene Mutation (A LUNG-MAP Treatment Trial)CompletedNCT04173507Phase 2Results posted
• Ramucirumab and Pembrolizumab Versus Standard of Care in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Non-Match Treatment Trial)CompletedNCT03971474Phase 2Results posted
• Treatment Effects on Development of Chemotherapy-Induced Peripheral Neuropathy in Patients With CancerActive, not recruitingNCT03939481Results posted
• Rucaparib in Treating Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)CompletedNCT03845296Phase 2Results posted
• S1415CD, Trial Assessing CSF Prescribing Effectiveness and Risk (TrACER)CompletedNCT02728596Not applicableResults posted
• S1403, Afatinib Dimaleate With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage IV or Recurrent, EGFR Mutation Positive Non-small Cell Lung CancerCompletedNCT02438722Phase 2/3Results posted
• S1300: Pemetrexed Disodium With or Without Crizotinib in Treating Patients With Stage IV Non-Small Cell Lung Cancer That Has Progressed After CrizotinibTerminatedNCT02134912Phase 2Results posted
• S0720: Adjuvant Therapy Based on Gene Expression in Stage IA and IB Non-Small Cell Lung CancerCompletedNCT00792701Phase 2Results posted
• S0709: Erlotinib With or Without Carboplatin and Paclitaxel in Stage IIIB or Stage IV Non-Small Cell Lung CancerCompletedNCT00661193Phase 2Results posted
• S0429: Docetaxel, Cetuximab, and Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung CancerTerminatedNCT00288054Phase 1Results posted
• Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung StudyActive, not recruitingNCT05633602Phase 3
• Testing the Use of Targeted Treatment for RET Positive Advanced Non-small Cell Lung CancerWithdrawnNCT05364645Phase 2
• Testing the Use of Combination Immunotherapy Treatment (N-803 [ALT-803] Plus Pembrolizumab) Against the Usual Treatment for Advanced Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)Active, not recruitingNCT05096663Phase 2/3
• Testing the Use of Targeted Treatment (AMG 510) for KRAS G12C Mutated Advanced Non-squamous Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)Active, not recruitingNCT04625647Phase 2
• Targeted Treatment for RET Fusion-Positive Advanced Non-Small Cell Lung Cancer (A LUNG-MAP Treatment Trial)Active, not recruitingNCT04268550Phase 2
• S0424 - Carcinogens in Lung Tissue From Smokers (Closed to Entry as of 7/15/07) and Non-Smokers With Newly Diagnosed Stage I, Stage II, or Stage III Non-Small Cell Lung CancerCompletedNCT00450281
• S0342: Paclitaxel, Carboplatin, and Cetuximab in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung CancerCompletedNCT00085501Phase 2
• S0002 - A Program to Quit Smoking With or Without Bupropion in Treating Patients With Stage I or II Non-Small Cell Lung Cancer Who Have Undergone SurgeryTerminatedNCT00032084Phase 3
• S0027: Vinorelbine Followed by Docetaxel in Treating Patients With Advanced Non-Small Cell Lung CancerCompletedNCT00026156Phase 2
• S0022:Combination Chemotherapy and Radiation Therapy in Treating Patients With Stage IIIB Non-Small Cell Lung CancerTerminatedNCT00014196Phase 2
• Combination Chemotherapy With or Without Tirapazamine in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung CancerCompletedNCT00006484Phase 3
• S9900: Surgery With or Without Combination Chemotherapy in Treating Patients With Non-small Cell Lung CancerCompletedNCT00004011Phase 3
• S9806: Combination Chemotherapy in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung CancerCompletedNCT00003587Phase 2
• S9712: Radiation Therapy and Combination Chemotherapy in Treating Patients With Stage III Non-small Cell Lung CancerCompletedNCT00003158Phase 2
• SWOG-9416: Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With Stage III Non-small Cell Lung CancerCompletedNCT00002642Phase 2